PET imaging study for normal aging, MCI, and Alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a new PET imaging agent (18F-XTR006) to see how well it shows brain changes related to Alzheimer's disease. It may help diagnose MCI (mild cognitive impairment) or Alzheimer's earlier by comparing images in healthy people and those with memory problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older.
- You can have both a PET scan and an MRI scan.
- If you can become pregnant, you must use birth control during the study and for 6 months after.
- You do not have other types of dementia, major mental illness, brain abnormalities, claustrophobia, or a history of alcohol or drug abuse.
- You are not allergic to the study drug and are not breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a PET scan “tracer” medicine called [18F]MK-6240 to see how tau protein changes show up in the brain. It may help researchers measure disease-related brain changes in people with normal thinking or mild dementia.
This trial uses a special PET scan tracer to see if it can predict who will get worse over time. It is for people with mild memory or thinking problems that may be linked to past head injuries or early Alzheimer's disease.
This study uses a PET brain scan with a small injected tracer to look for “tau” protein changes linked to Alzheimer’s disease. It may help researchers better understand how tau appears in people who are cognitively normal or have mild dementia.
This study compares two types of brain PET scans (tau and amyloid) to see which one better helps diagnose memory problems. You may be eligible if you have mild cognitive impairment or mild dementia and your doctor has already ordered an amyloid PET scan.
This early-phase study tests a new PET scan tracer that targets a brain chemical transport system involved in dementia. It aims to see if the tracer can safely and clearly show brain changes, which could help future dementia diagnosis or tracking.
This study uses a special PET brain scan to look at two types of brain immune cells in people with Alzheimer’s. It may help researchers better understand Alzheimer’s and how these cells change over time.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.